期刊
ONCOGENE
卷 34, 期 1, 页码 129-134出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2013.534
关键词
EGFRvIII; glioblastoma; EGFR wild type; Met; antagonistic interaction; temozolomide
资金
- NIH [RO1N5062080, RO1 CA139217]
- National Institutes of Health [RO1 CA149461, R01-DK63621, R01-CA134571]
- National Aeronautics and Space Administration [NNX13AI13G]
- Cancer Prevention and Research Institute of Texas [RP100644]
- Office of Medical Research, Departments of Veterans Affairs (RFS)
Epidermal growth factor receptor (EGFR)vIII is the most common EGFR mutant found in glioblastoma (GBM). EGFRvIII does not bind ligand, is highly oncogenic and is usually coexpressed with EGFR wild type (EGFRwt). EGFRvIII activates Met, and Met contributes to EGFRvIII-mediated oncogenicity and resistance to treatment. Here, we report that addition of EGF results in a rapid loss of EGFRvIII-driven Met phosphorylation in glioma cells. Met is associated with EGFRvIII in a physical complex. Addition of EGF results in a dissociation of the EGFRvIII-Met complex with a concomitant loss of Met phosphorylation. Consistent with the abrogation of Met activation, addition of EGF results in the inhibition of EGFRvIII-mediated resistance to chemotherapy. Thus, our study suggests that ligand in the milieu of EGFRvIII-expressing GBM cells is likely to influence the EGFRvIII-Met interaction and resistance to treatment, and highlights a novel antagonistic interaction between EGFRwt and EGFRvIII in glioma cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据